International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2026   Volume 16   Issue 2

Benchmarking AI for Natural Product Drug Discovery: Data Integrity, Model Robustness, Mechanistic Validity, and Translational Utility
Download PDF


, ,
  1. Department of Artificial Intelligence for Anti-obesity Phytochemicals, Faculty of Pharmacy, University of Leeds, Leeds, United Kingdom.
  2. Department of Machine Learning for Lipase Inhibition, Faculty of Pharmacy, University of Sheffield, Sheffield, United Kingdom.
Citation
Vancouver
Wright E, Bennett C, Turner J. Benchmarking AI for Natural Product Drug Discovery: Data Integrity, Model Robustness, Mechanistic Validity, and Translational Utility. Int J Pharm Phytopharmacol Res. 2026;16(2):1-18. https://doi.org/10.51847/iPQZ02GzuS
APA
Wright, E., Bennett, C., & Turner, J. (2026). Benchmarking AI for Natural Product Drug Discovery: Data Integrity, Model Robustness, Mechanistic Validity, and Translational Utility. International Journal of Pharmaceutical And Phytopharmacological Research, 16(2), 1-18. https://doi.org/10.51847/iPQZ02GzuS
Download citation:   EndNote   RIS
Article Link:
Downloads: 22
Views: 102
Abstract

Artificial intelligence is increasingly used to support natural product identification, bioactivity prediction, target inference, molecular property estimation, and candidate prioritization, yet model evaluation frequently remains dominated by aggregate predictive performance. Such evaluation can obscure structural errors, unreliable annotations, data leakage, narrow chemical-space coverage, distribution shifts, mechanistic uncertainty, and limited relevance to experimental decision-making. This article proposes a conceptual benchmarking framework for AI in natural product drug discovery that organizes evaluation around four interdependent dimensions: data integrity, model robustness, mechanistic validity, and translational utility. The framework begins with natural product identity, chemical structure, stereochemistry, provenance, bioactivity, assay, target, and safety-data audits. It then requires task-aligned split strategies, transparent baseline comparisons, external and out-of-distribution testing, perturbation analysis, uncertainty estimation, bias assessment, and reproducibility documentation. Mechanistic validity is treated as an evidence-integration problem involving compound–target support, biological context, pathway plausibility, omics consistency, assay relevance, exposure considerations, toxicity, and experimental perturbation. Translational utility is evaluated through experimental actionability, safety awareness, developability, source authenticity, external generalizability, implementation feasibility, and expert review. The proposed architecture establishes decision boundaries that prevent benchmark success from being interpreted as proof of mechanism, therapeutic efficacy, clinical utility, safety, deployment readiness, or regulatory acceptance. Its principal contribution is a structured evaluation logic intended to strengthen model comparison, expose limitations, guide research prioritization, and improve the credibility and reproducibility of AI-assisted natural product discovery.

Related articles:
Most viewed articles:
Naproxen in Pain and Inflammation – A Review
Vol 11 Issue 1, 2021 | Svetoslav Nikolaev Stoev
An Overview on Emulgel
Vol 9 Issue 1, 2019 | Sreevidya V.S
Volume 16
Issue 4
2026

Call for Papers
[email protected]
Issues
Associations
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2026 International Journal of Pharmaceutical and Phytopharmacological Research
Authors retain copyright of their article if they are accepted for publication.